메뉴 건너뛰기




Volumn 22, Issue 9, 2006, Pages 865-869

Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; BENZOXAZINONE DERIVATIVE; DIDANOSINE; EFAVIRENZ; IMMUNOGLOBULIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLASMA PROTEIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

EID: 33751030291     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.865     Document Type: Article
Times cited : (5)

References (15)
  • 1
    • 17044456283 scopus 로고    scopus 로고
    • Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients
    • Burrer R, Salmon-Ceron D, Richert S, et al.: Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J Virol 2001;75:5421-5424.
    • (2001) J Virol , vol.75 , pp. 5421-5424
    • Burrer, R.1    Salmon-Ceron, D.2    Richert, S.3
  • 2
    • 0036394419 scopus 로고    scopus 로고
    • Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08
    • Verrier B, Le Grand R, Ataman-Onal Y, et al.: Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol 2002;21:653-658.
    • (2002) DNA Cell Biol , vol.21 , pp. 653-658
    • Verrier, B.1    Le Grand, R.2    Ataman-Onal, Y.3
  • 3
    • 0032437454 scopus 로고    scopus 로고
    • The rule of non-nuclcoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
    • De Clercq E: The rule of non-nuclcoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153-179.
    • (1998) Antiviral Res , vol.38 , pp. 153-179
    • De Clercq, E.1
  • 4
    • 0032751029 scopus 로고    scopus 로고
    • Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients
    • Villani P, Regazzi MB, Castelli F, et al.: Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999;48:712-715.
    • (1999) Br J Clin Pharmacol , vol.48 , pp. 712-715
    • Villani, P.1    Regazzi, M.B.2    Castelli, F.3
  • 5
    • 0037320996 scopus 로고    scopus 로고
    • Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals
    • Mallon PW, Ray J, and Cooper DA: Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 2003;26:223-227.
    • (2003) J Clin Virol , vol.26 , pp. 223-227
    • Mallon, P.W.1    Ray, J.2    Cooper, D.A.3
  • 6
    • 0035875828 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    • Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
    • (2001) AIDS , vol.15 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3    Greub, G.4    Biollaz, J.5    Buclin, T.6
  • 7
    • 0141532404 scopus 로고    scopus 로고
    • DuPont Pharmaceuticals: DuPont Pharmaceuticals, Herfordshire, UK
    • DuPont Pharmaceuticals: Sustiva (Efavirenz product package insert) DuPont Pharmaceuticals, Herfordshire, UK, 1999.
    • (1999) Sustiva (Efavirenz Product Package Insert)
  • 8
    • 0029820967 scopus 로고    scopus 로고
    • Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease
    • Bilello JA and Drusano GL: Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infect Dis 1996;173:1524-1526.
    • (1996) J Infect Dis , vol.173 , pp. 1524-1526
    • Bilello, J.A.1    Drusano, G.L.2
  • 10
    • 0034128898 scopus 로고    scopus 로고
    • Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
    • Corbett JW, Ko SS, Rodgers JD, et al.: Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem 2000;43:2019-2030.
    • (2000) J Med Chem , vol.43 , pp. 2019-2030
    • Corbett, J.W.1    Ko, S.S.2    Rodgers, J.D.3
  • 11
    • 0028124660 scopus 로고
    • Bicycle imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1
    • Moog C, Wick A, Le Ber P, Kirn A, and Aubenin AM: Bicycle imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res 1994;24:275-288.
    • (1994) Antiviral Res , vol.24 , pp. 275-288
    • Moog, C.1    Wick, A.2    Le Ber, P.3    Kirn, A.4    Aubenin, A.M.5
  • 12
    • 0037419657 scopus 로고    scopus 로고
    • Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography
    • Turner ML, Reed-Walker K, King JR, and Acosla EP: Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B 2003;784:331-341.
    • (2003) J Chromatogr B , vol.784 , pp. 331-341
    • Turner, M.L.1    Reed-Walker, K.2    King, J.R.3    Acosla, E.P.4
  • 13
    • 0035025888 scopus 로고    scopus 로고
    • A quantitative assay for HIV DNA integration in vivo
    • Butler SM, Hansen MS, and Bushman FD: A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631-634.
    • (2001) Nat Med , vol.7 , pp. 631-634
    • Butler, S.M.1    Hansen, M.S.2    Bushman, F.D.3
  • 14
    • 0037542551 scopus 로고    scopus 로고
    • Once-a-day highly active antiretioviral therapy: A systematic review
    • Ena J and Pasquau F: Once-a-day highly active antiretioviral therapy: A systematic review. Clin Infect Dis 2003;36:1186-1190.
    • (2003) Clin Infect Dis , vol.36 , pp. 1186-1190
    • Ena, J.1    Pasquau, F.2
  • 15
    • 0346992391 scopus 로고    scopus 로고
    • Nevirapine plus efavirenz plus didanosine: A simple, safe, and effective once-daily regimen for patients with HIV infection
    • Jordan WC, Jefferson R, Yemofio F, et al.: Nevirapine plus efavirenz plus didanosine: A simple, safe, and effective once-daily regimen for patients with HIV infection. Natl Med Assoc 2003;95:1152-1157.
    • (2003) Natl Med Assoc , vol.95 , pp. 1152-1157
    • Jordan, W.C.1    Jefferson, R.2    Yemofio, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.